Biohaven Ltd. (BHVN)

Market Cap	2.08B
Revenue (ttm)	n/a
Net Income (ttm)	-846.42M
Shares Out	102.06M
EPS (ttm)	-9.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,097,939
Open	19.02
Previous Close	18.68
Day's Range	19.02 - 20.48
52-Week Range	15.79 - 55.70
Beta	4.15
Analysts	Strong Buy
Price Target	63.15 (+210.32%)
Earnings Date	May 8, 2025

About BHVN

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 256
• Stock Exchange: NYSE
• Ticker Symbol: BHVN
• Website: https://www.biohaven.com

Analyst Forecast

According to 14 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $63.15, which is an increase of 210.32% from the latest price.

Price Target

$63.15

(210.32% upside)

Analyst Consensus: Strong Buy